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In a recent study published in New England Journal of 
Medicine, Pan and colleagues1 faced an important aspect 
for prevention of hepatitis B virus (HBV) infection: anti-
viral treatment with Tenofovir (TDF) during pregnancy 
to reduce perinatal transmission. This route of infec-
tion plays a crucial role for global diffusion of HBV, 
with frequency of chronic infection in mother-to-child- 
transmission (MTCT) of 90%.
The results by Pan and colleagues show that TDF 
treatment during pregnancy significantly reduces the 
transmission rate compared to the standard prophylaxis 
recommended by World Health Organization (WHO),2 
that leaves a residual HBV transmission mostly in highly 
viremic mothers (>200,000 IU/mL HBV-DNA). Thus, 
reduction of the viral load at delivery by antiviral treatment 
is an attractive possibility in reducing MTCT. Indeed, in a 
recent simulation model of the global HBV epidemic, scal-
ing up the use of peripartum antivirals (to 80% of HBeAg 
positive mothers), together with other interventions, was 
indicated as an important strategy to avert 7.3 million 
deaths between 2015 and 2030.3
Earlier reports have shown conflicting results but, 
according to recent WHO guidelines,2 quality scores of 
some studies were low, highlighting the need for further, 
more carefully designed ones. Pan et al. performed a mul-
ticenter, open-label, randomized, parallel-group study, 
enrolling 200 highly viremic mothers. The reliability of 
the results was significantly improved by a proper exper-
imental design. The primary outcomes (transmission rate 
and birth defects) were assessed at 28 weeks after birth, 
a longer follow-up than in previous studies. In addition, 
monitoring of maternal viral load convincingly demon-
strated, in 68% mothers, reduction of viremia at delivery 
below the 200,000 IU/mL, considered to be the threshold 
value for significant decrease of MTCT.
The results support the efficacy of TDF to pre-
vent MTCT in highly viremic mothers (median value: 
8.18 log10 IU/mL or 151,000,000 IU/mL). Treatment was 
beneficial, since in the per-protocol analysis none of the 
infants born to compliant mothers resulted in infection by 
HBV compared to 7% of controls (p = 0.01). Moreover, 
the short-term safety reported in the study confirms data 
from HIV-infected pregnant women.4 However, some fun-
damental questions remain unanswered.
The first regards the best time to start treatment during 
pregnancy. Treatment initiation may be a relevant issue 
since adherence may be suboptimal out of a controlled 
study, and there is a possibility that the later the treatment 
is started the more significant the effect of nonadherence 
is on the virological control. The antiretroviral pregnancy 
registry, which reports the overall rate of birth defects 
observed in children born to mothers treated during the 
entire pregnancy, indicates that such rates for lamivu-
dine and TDF is similar to the general population (2.8% 
vs. 2.72%).5 Therefore early treatment could be a viable 
option.
The second point is related to safety of breastfeeding 
in treated mothers. In the study of Pan et al., breastfeeding 
was banned for mothers taking TDF during the first four 
weeks after delivery. In HIV-mothers, TDF concentrations 
in breast milk are reported to be very low, ranging from 
17.6 ng/mL to undetectable levels one week after delivery6 
and the median plasma concentration detected in breastfed 
children at 6 months of age was 24 ng/mL.7 Examination 
of breast milk TDF concentration could have been an inter-
esting result that arose from this study, but it was missed. 
However, preventing mothers to be breastfed may repre-
sent a significant problem in some highly endemic areas 
of the world where interrupting HBV MTCT is extremely 
important, but breastfeeding is an essential key resource.
Finally, the results of this study should prompt action 
to overcome the existing limitations. One of which could 
be the assessment of viral load in areas where HBV is 
highly prevalent but the economic resources are scarce. 
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This will be seen in the form of a phase III, multicenter, 
placebo-controlled, double-blind, randomized (1:1) clini-
cal trial that will be conducted in Thailand and will enroll 
more than 300 pregnant women, the only virological inclu-
sion criterion will be HBeAg-positivity, irrespective of 
HBV-DNA level.8 Examining the results of this trial will 
be extremely important to plan prevention campaigns, 
especially in countries with limited access to facilities 
with high virological diagnostic skills.
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